Patient-friendly injections

Nobody likes getting an injection at the doctor’s office. However, pharmaceutical and biotechnology companies can now partner with 3M scientists on developing and conducting clinical trials using 3M’s Hollow Microstructured Transdermal System (hMTS) following the device’s completion of a number of studies and design verification tests.

Using 3M microreplication technology, the patient-friendly hollow microneedle device can be used for difficult-to-deliver biologics.

To reach clinical readiness with the hMTS device, 3M has finalized the device design, manufactured critical components from medical-grade materials, established GMP array manufacturing and device assembly, and filed documentation with the Food and Drug Administration.

A 3M human tolerability study to select the appropriate microneedle array for clinical studies found very good delivery times for 2mL (less than 2 min. on average). These results provide foundational data in assessing the safety of the device. Clinical supplies are now available for assessment in potential development partners’ trials.

“Pharma companies can now evaluate 3M hMTS in their clinical trials as a delivery system for a new drug product or a product line extension,” says Ingrid Blair, vice president, business and marketing, 3M Drug Delivery Systems. “Keeping patient preference top of mind is key, and with this new system, pharmaceutical companies have more options to satisfy patients.”

Benefits of the hMTS system include reproducible intradermal delivery, ability to deliver formulations with various viscosities, and API-dependent PK profile benefits. By collaborating with 3M, companies can bring the microneedle drug-delivery alternative to market sooner, rather than later.
 

3M
www.3M.com